Intercell Signs Exclusive Agreement for Marketing and Distribution of its Japanese Encephalitis Vaccine in Japan and Korea

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

cooperations

Wien (euro adhoc) - Vienna (Austria), January 19, 2009 - Intercell AG
(VSE: ICLL) announced it has signed an exclusive agreement with
Novartis AG for the marketing and distribution of Intercell's vaccine
candidate to prevent Japanese Encephalitis, in Japan and Korea. This
expands the commercialization agreement between Intercell and
Novartis to these territories, which previously were not covered by
the initial marketing and distribution agreement for Intercell's
Japanese Encephalitis vaccine signed in 2006. Under the terms of this
agreement, Novartis receives the exclusive marketing and distribution
rights in Japan and Korea and obtains a distribution margin on all
product sales in these territories. Additional financial details were
not disclosed.

"Japanese Encephalitis is endemic to Japan and Korea and poses a
significant risk, particularly to children", said Gerd Zettlmeissl,
Chief Executive Officer of Intercell. "It was a priority for
Intercell to identify a very strong marketing partner for these
markets, where the disease is a major public health threat and we are
convinced that Novartis - with its global reach - is ideally suited."

About Japanese Encephalitis

Japanese Encephalitis is a mosquito-borne infection that strikes
30,000 to 50,000 individuals a year, causing 10,000 to 15,000 deaths.
Up to 50% of survivors have persistent neurological sequelae.
Japanese Encephalitis is the leading cause of viral neurological
disease and disability in Asia and the most important viral
encephalitis in Asia. The disease is most common in several
developing countries in Asia. No treatment is currently available;
only vaccination effectively prevents the disease. Though other
vaccines have been available in the past, use of those products was
limited due to reports of neurological reactions.

About Intercell's JE vaccine

Intercell's novel JE vaccine is a purified, inactivated vaccine for
active immunization against the Japanese Encephalitis virus. The
vaccine was developed for over 10 years under a Collaborative
Research and Development Agreement (CRADA) with the Walter Reed Army
Institute of Research (WRAIR). Intercell's Phase III trials for the
vaccine found that the vaccine demonstrated excellent immunogenicity
against Japanese Encephalitis and an overall clinical safety profile
similar to placebo combined with an excellent local tolerability
profile. These data were published in The Lancet in December 2007:

» The immunogenicity was comparable to that of the U.S. licensed
product, JE-VAX® » Intercell's vaccine demonstrated an overall
clinical safety profile similar to placebo » Further, Intercell's
JE vaccine had an excellent local tolerability profile in the
head-to-head study with JE-VAX®

In December 2008 Intercell AG received the CHMP (European Committee
for Human Medicinal Products) positive opinion for the approval of
its vaccine in Europe. Furthermore, the Australian Drug Evaluation
Committee (ADEC) has issued a positive approval recommendation for
the company´s new vaccine against Japanese Encephalitis.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market